ANN ARBOR, Michigan — NanoBio Corp. has been awarded a U.S. patent related to technology used in the company’s anti-infection and dermatology drugs, according to a statement.
The award marks the sixth patent the Ann Arbor-based company has received for its nanoemulsion technology, in which ultra-small particles of one liquid are suspended in a second liquid that won’t mix with the first.
The company has several drugs under development, all based on its Nanostat technology platform, which delivers drugs through the skin or nasal passages rather than using needles.
Price Transparency is the New North in the PBM World
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
NanoBio hit a major milestone in December, when it signed a licensing deal with pharmaceuticals giant GlaxoSmithKline for its cold sore drug. The licensing agreement, the company’s first, could be worth more than $54 million to NanoBio. The company plans to begin testing the drug, NB-001, in Phase 3 trials soon.
The company also completed a Phase 1 study of its seasonal influenza vaccine candidate, which is administered via a nasal dropper. That drug, NB-1008, looks to be the second for which the company will sign a licensing deal. NanoBio says it’s in discussions “with several parties” regarding a potential agreement.
NanoBio has raised more than $90 million in grants and venture funding since its inception in 2000. In July, the company closed a $22 million Series B round that will fund its operations through 2011.
In addition to its cold sore and influenza drugs, NanoBio is working to develop treatments for nail fungus, acne and cystic fibrosis.
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
The company is based on technology pioneered at the University of Michigan by Dr. James R. Baker Jr., the company’s founder and chief executive.